Patents by Inventor Elizabeth Light
Elizabeth Light has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220193196Abstract: The present invention relates to methods, compositions, and kits for increasing the activation of effector T cells in a subject or inhibiting the activation of effector T cells in a subject by increasing or decreasing TNFR2 (CD 120b) signaling respectively. The present invention also relates to methods, compositions, and kits for treating diseases such as cancer, infections, and autoimmune diseases.Type: ApplicationFiled: May 27, 2020Publication date: June 23, 2022Inventors: Edwin Hawkins, Najoua Lalaoui, Amanda Elizabeth Light, Mark McKenzie, John Silke
-
Publication number: 20220177951Abstract: A method of screening for the presence and/or extent of a pathology in a subject, the pathology characterized by an abnormal chromosomal component in a cell of the subject, comprising the steps of: contacting a biological sample comprising cell nuclei from said subject with, one or more distinguishable labeled probes directed to at least one chromosomal sequence that characterizes the abnormality under conditions that promote hybridization of the one or more probes to the at least one sequence, automatically obtaining a representation of the one or more distinguishable labels hybridized to the chromosomal sequences, automatically analyzing the distribution and intensity of binding of the one or more labels in the representation to determine the presence and/or extent of an abnormal chromosomal component; and automatically reporting results of the analysis: wherein the steps are carried out without intervention by a human.Type: ApplicationFiled: November 18, 2021Publication date: June 9, 2022Applicant: NeoDiagnostix, Inc.Inventors: Gregory Anton Endress, Madhvi Upender, Elizabeth Light, Colyn Cargile Cain
-
Publication number: 20220049320Abstract: The invention provides for a diagnostic test to monitor cancer-specific genetic abnormalities to diagnose cervical cell disorders and predict which patients might progress to cancer. Genetic abnormalities are detected by identification in chromosomal copy number of chromosome 3 and chromosome 5 using FISH analysis of probes targeted to 3q and/or 5p.Type: ApplicationFiled: October 31, 2021Publication date: February 17, 2022Applicant: NeoDiagnostix, Inc.Inventors: Gregory Anton Endress, Madhvi Upender, Elizabeth Light, Colyn Cargile Cain
-
Patent number: 11193160Abstract: A method of screening for the presence and/or extent of a pathology in a subject, the pathology characterized by an abnormal chromosomal component in a cell of the subject, comprising the steps of: contacting a biological sample comprising cell nuclei from said subject with, one or more distinguishable labeled probes directed to at least one chromosomal sequence that characterizes the abnormality under conditions that promote hybridization of the one or more probes to the at least one sequence, automatically obtaining a representation of the one or more distinguishable labels hybridized to the chromosomal sequences, automatically analyzing the distribution and intensity of binding of the one or more labels in the representation to determine the presence and/or extent of an abnormal chromosomal component; and automatically reporting results of the analysis; wherein the steps are carried out without intervention by a human.Type: GrantFiled: March 17, 2019Date of Patent: December 7, 2021Assignee: NeoDiagnostix, Inc.Inventors: Gregory Anton Endress, Madhvi Upender, Elizabeth Light, Colyn Cargile Cain
-
Patent number: 11162140Abstract: The invention provides for a panel for detecting chromosomal abnormalities in a plurality of cells in a cervical sample wherein the panel comprises a plurality of fluorescently labeled probes individually capable of hybridizing to specific chromosomal locations associated with a chromosomal abnormality in patients at risk for a cervical cell disorder. The invention also comprises a fluorescence in situ hybridization (FISH) probe set comprising the plurality of fluorescently labeled probes.Type: GrantFiled: November 7, 2016Date of Patent: November 2, 2021Assignee: NeoDiagnostix, Inc.Inventors: Gregory Anton Endress, Madhvi Upender, Elizabeth Light, Colyn Cain
-
Publication number: 20190211382Abstract: A method of screening for the presence and/or extent of a pathology in a subject, the pathology characterized by an abnormal chromosomal component in a cell of the subject, comprising the steps of: contacting a biological sample comprising cell nuclei from said subject with, one or more distinguishable labeled probes directed to at least one chromosomal sequence that characterizes the abnormality under conditions that promote hybridization of the one or more probes to the at least one sequence, automatically obtaining a representation of the one or more distinguishable labels hybridized to the chromosomal sequences, automatically analyzing the distribution and intensity of binding of the one or more labels in the representation to determine the presence and/or extent of an abnormal chromosomal component; and automatically reporting results of the analysis; wherein the steps are carried out without intervention by a human.Type: ApplicationFiled: March 17, 2019Publication date: July 11, 2019Applicant: NeoDiagnostix, Inc.Inventors: Gregory Anton Endress, Madhvi Upender, Elizabeth Light, Colyn Cargile Cain
-
Publication number: 20170067123Abstract: The invention provides for a diagnostic test to monitor cancer-specific genetic abnormalities to diagnose cervical cell disorders and predict which patients might progress to cancer. Genetic abnormalities are detected by identification in chromosomal copy number of chromosome 3 and 5 using FISH analysis of probes targeted to 3q and/or 5p.Type: ApplicationFiled: November 7, 2016Publication date: March 9, 2017Inventors: Gregory Anton Endress, Madhvi Upender, Elizabeth Light, Colyn Cain
-
Patent number: 9562270Abstract: The invention provides for a diagnostic test to monitor cancer-specific genetic abnormalities to diagnose cervical cell disorders and predict which patients might progress to cancer. Genetic abnormalities are detected by identification in chromosomal copy number of chromosome 3 and chromosome 5 using FISH analysis of probes targeted to 3q and/or 5p.Type: GrantFiled: May 27, 2015Date of Patent: February 7, 2017Assignee: NeoDiagnostixInventors: Gregory Anton Endress, Madhvi Upender, Elizabeth Light, Colyn Cain
-
Publication number: 20160153048Abstract: The invention provides for a diagnostic test to monitor cancer-specific genetic abnormalities to diagnose cervical cell disorders and predict which patients might progress to cancer. Genetic abnormalities are detected by identification in chromosomal copy number of chromosome 3 and chromosome 5 using FISH analysis of probes targeted to 3q and/or 5p.Type: ApplicationFiled: May 27, 2015Publication date: June 2, 2016Inventors: Gregory Anton Endress, Madhvi Upender, Elizabeth Light, Colyn Cain
-
Patent number: 9080203Abstract: A method of screening for the presence and/or extent of a pathology in a subject, the pathology characterized by an abnormal chromosomal component in a cell of the subject, comprising the steps of: contacting a biological sample comprising cell nuclei from said subject with, one or more distinguishable labeled probes directed to at least one chromosomal sequence that characterizes the abnormality under conditions that promote hybridization of the one or more probes to the at least one sequence, automatically obtaining a representation of the one or more distinguishable labels hybridized to the chromosomal sequences, automatically analyzing the distribution and intensity of binding of the one or more labels in the representation to determine the presence and/or extent of an abnormal chromosomal component; and automatically reporting results of the analysis; wherein the steps are carried out without intervention by a human.Type: GrantFiled: September 3, 2014Date of Patent: July 14, 2015Assignee: NeoDiagnostix, Inc.Inventors: Gregory Anton Endress, Madhvi Upender, Elizabeth Light, Colyn Cain
-
Patent number: 9051607Abstract: The invention provides for a diagnostic test to monitor cancer-specific genetic abnormalities to diagnose cervical cell disorders and predict which patients might progress to cancer. Genetic abnormalities are detected by identification in chromosomal copy number of chromosome 3 and chromosome 5 using FISH analysis of probes targeted to 3q and/or 5p.Type: GrantFiled: April 29, 2014Date of Patent: June 9, 2015Assignee: NeoDiagnostix, Inc.Inventors: Gregory Anton Endress, Madhvi Upender, Elizabeth Light, Colyn Cain
-
Publication number: 20150024394Abstract: A method of screening for the presence and/or extent of a pathology in a subject, the pathology characterized by an abnormal chromosomal component in a cell of the subject, comprising the steps of: contacting a biological sample comprising cell nuclei from said subject with, one or more distinguishable labeled probes directed to at least one chromosomal sequence that characterizes the abnormality under conditions that promote hybridization of the one or more probes to the at least one sequence, automatically obtaining a representation of the one or more distinguishable labels hybridized to the chromosomal sequences, automatically analyzing the distribution and intensity of binding of the one or more labels in the representation to determine the presence and/or extent of an abnormal chromosomal component; and automatically reporting results of the analysis; wherein the steps are carried out without intervention by a human.Type: ApplicationFiled: September 3, 2014Publication date: January 22, 2015Inventors: Gregory Anton Endress, Madhvi Upender, Elizabeth Light, Colyn Cain
-
Publication number: 20150024395Abstract: A method of screening for the presence and/or extent of a pathology in a subject, the pathology characterized by an abnormal chromosomal component in a cell of the subject, comprising the steps of: contacting a biological sample comprising cell nuclei from said subject with, one or more distinguishable labeled probes directed to at least one chromosomal sequence that characterizes the abnormality under conditions that promote hybridization of the one or more probes to the at least one sequence, automatically obtaining a representation of the one or more distinguishable labels hybridized to the chromosomal sequences, automatically analyzing the distribution and intensity of binding of the one or more labels in the representation to determine the presence and/or extent of an abnormal chromosomal component; and automatically reporting results of the analysis; wherein the steps are carried out without intervention by a human.Type: ApplicationFiled: September 3, 2014Publication date: January 22, 2015Inventors: Gregory Anton Endress, Madhvi Upender, Elizabeth Light, Colyn Cain
-
Publication number: 20150024393Abstract: A method of screening for the presence and/or extent of a pathology in a subject, the pathology characterized by an abnormal chromosomal component in a cell of the subject, comprising the steps of: contacting a biological sample comprising cell nuclei from said subject with, one or more distinguishable labeled probes directed to at least one chromosomal sequence that characterizes the abnormality under conditions that promote hybridization of the one or more probes to the at least one sequence, automatically obtaining a representation of the one or more distinguishable labels hybridized to the chromosomal sequences, automatically analyzing the distribution and intensity of binding of the one or more labels in the representation to determine the presence and/or extent of an abnormal chromosomal component; and automatically reporting results of the analysis; wherein the steps are carried out without intervention by a human.Type: ApplicationFiled: September 3, 2014Publication date: January 22, 2015Inventors: Gregory Anton Endress, Madhvi Upender, Elizabeth Light, Colyn Cain
-
Patent number: 8852865Abstract: A method of screening for the presence and/or extent of a pathology in a subject, the pathology characterized by an abnormal chromosomal component in a cell of the subject, comprising the steps of: contacting a biological sample comprising cell nuclei from said subject with, one or more distinguishable labeled probes directed to at least one chromosomal sequence that characterizes the abnormality under conditions that promote hybridization of the one or more probes to the at least one sequence, automatically obtaining a representation of the one or more distinguishable labels hybridized to the chromosomal sequences, automatically analyzing the distribution and intensity of binding of the one or more labels in the representation to determine the presence and/or extent of an abnormal chromosomal component; and automatically reporting results of the analysis; wherein the steps are carried out without intervention by a human.Type: GrantFiled: November 1, 2013Date of Patent: October 7, 2014Assignee: NeoDiagnostix, Inc.Inventors: Gregory Anton Endress, Madhvi Upender, Elizabeth Light, Colyn Cain
-
Publication number: 20140234839Abstract: The invention provides for a diagnostic test to monitor cancer-specific genetic abnormalities to diagnose cervical cell disorders and predict which patients might progress to cancer. Genetic abnormalities are detected by identification in chromosomal copy number of chromosome 3 and chromosome 5 using FISH analysis of probes targeted to 3q and/or 5p.Type: ApplicationFiled: April 29, 2014Publication date: August 21, 2014Applicant: NeoDiagnostixInventors: Gregory Anton Endress, Madhvi Upender, Elizabeth Light, Colyn Cain
-
Patent number: 8748099Abstract: The invention provides for a diagnostic test to monitor cancer-specific genetic abnormalities to diagnose cervical cell disorders and predict which patients might progress to cancer. Genetic abnormalities are detected by identification in chromosomal copy number of chromosome 3 and chromosome 5 using FISH analysis of probes targeted to 3q and/or 5p.Type: GrantFiled: November 1, 2013Date of Patent: June 10, 2014Assignee: NeoDiagnostix, Inc.Inventors: Gregory Anton Endress, Madhvi Upender, Elizabeth Light, Colyn Cain
-
Publication number: 20140135229Abstract: A method of screening for the presence and/or extent of a pathology in a subject, the pathology characterized by an abnormal chromosomal component in a cell of the subject, comprising the steps of: contacting a biological sample comprising cell nuclei from said subject with, one or more distinguishable labeled probes directed to at least one chromosomal sequence that characterizes the abnormality under conditions that promote hybridization of the one or more probes to the at least one sequence, automatically obtaining a representation of the one or more distinguishable labels hybridized to the chromosomal sequences, automatically analyzing the distribution and intensity of binding of the one or more labels in the representation to determine the presence and/or extent of an abnormal chromosomal component; and automatically reporting results of the analysis; wherein the steps are carried out without intervention by a human.Type: ApplicationFiled: November 1, 2013Publication date: May 15, 2014Applicant: NeoDiagnostix IncInventors: Gregory Anton Endress, Madhvi Upender, Elizabeth Light, Colyn Cain
-
Publication number: 20140135228Abstract: The invention provides for a diagnostic test to monitor cancer-specific genetic abnormalities to diagnose cervical cell disorders and predict which patients might progress to cancer. Genetic abnormalities are detected by identification in chromosomal copy number of chromosome 3 and chromosome 5 using FISH analysis of probes targeted to 3q and/or 5p.Type: ApplicationFiled: November 1, 2013Publication date: May 15, 2014Applicant: NeoDiagnostixInventors: Gregory Anton Endress, Madhvi Upender, Elizabeth Light, Colyn Cain
-
Patent number: 8603746Abstract: The invention provides for a diagnostic test to monitor cancer-specific genetic abnormalities to diagnose cervical cell disorders and predict which patients might progress to cancer. Genetic abnormalities are detected by identification in chromosomal copy number of chromosome 3 and chromosome 5 using FISH analysis of probes targeted to 3q and/or 5p.Type: GrantFiled: July 21, 2009Date of Patent: December 10, 2013Assignee: NeoDiagnostix, Inc.Inventors: Gregory Anton Endress, Madhvi Upender, Elizabeth Light, Colyn Cain